HRP940267A2 - Veterinary composition - Google Patents
Veterinary composition Download PDFInfo
- Publication number
- HRP940267A2 HRP940267A2 HR9301489-2A HRP940267A HRP940267A2 HR P940267 A2 HRP940267 A2 HR P940267A2 HR P940267 A HRP940267 A HR P940267A HR P940267 A2 HRP940267 A2 HR P940267A2
- Authority
- HR
- Croatia
- Prior art keywords
- ingredients
- pharmaceutical preparation
- preparation according
- tablets
- small intestine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 229940126409 proton pump inhibitor Drugs 0.000 claims abstract description 22
- 239000000612 proton pump inhibitor Substances 0.000 claims abstract description 22
- 241001465754 Metazoa Species 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 210000004211 gastric acid Anatomy 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims description 25
- 239000004615 ingredient Substances 0.000 claims description 25
- 210000000813 small intestine Anatomy 0.000 claims description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 20
- 239000011248 coating agent Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 229960000381 omeprazole Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 9
- 241000283086 Equidae Species 0.000 claims description 7
- 239000006179 pH buffering agent Substances 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000005086 pumping Methods 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 5
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical group COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 229960003174 lansoprazole Drugs 0.000 claims description 4
- 229960005019 pantoprazole Drugs 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical group CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 229950007395 leminoprazole Drugs 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 abstract description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 18
- 239000000499 gel Substances 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000007931 coated granule Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- 230000027119 gastric acid secretion Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 for example Chemical class 0.000 description 4
- 229920000896 Ethulose Polymers 0.000 description 3
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 3
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000011240 wet gel Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 241000283201 Odobenidae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE19939301489A SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Veterinary composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP940267A2 true HRP940267A2 (en) | 1996-10-31 |
Family
ID=20389791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR9301489-2A HRP940267A2 (en) | 1993-04-30 | 1994-04-22 | Veterinary composition |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5731002A (no) |
| EP (1) | EP0696921B1 (no) |
| JP (1) | JP3872509B2 (no) |
| KR (1) | KR100324451B1 (no) |
| CN (1) | CN1100570C (no) |
| AT (1) | ATE199060T1 (no) |
| AU (1) | AU678830B2 (no) |
| BR (1) | BR9406363A (no) |
| CZ (1) | CZ285191B6 (no) |
| DE (1) | DE69426669T2 (no) |
| DK (1) | DK0696921T3 (no) |
| EE (1) | EE03137B1 (no) |
| EG (1) | EG20401A (no) |
| ES (1) | ES2155473T3 (no) |
| FI (1) | FI955124A0 (no) |
| GR (1) | GR3035831T3 (no) |
| HR (1) | HRP940267A2 (no) |
| HU (1) | HUT74868A (no) |
| IL (1) | IL109245A (no) |
| IS (1) | IS1694B (no) |
| LT (1) | LT3263B (no) |
| MA (1) | MA23170A1 (no) |
| NO (1) | NO312435B1 (no) |
| NZ (1) | NZ265728A (no) |
| PL (1) | PL176755B1 (no) |
| PT (1) | PT696921E (no) |
| RU (1) | RU2131267C1 (no) |
| SE (1) | SE9301489D0 (no) |
| SG (1) | SG52540A1 (no) |
| SK (1) | SK280465B6 (no) |
| TN (1) | TNSN94035A1 (no) |
| WO (1) | WO1994025070A1 (no) |
| YU (1) | YU22794A (no) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| ES2194515T3 (es) * | 1998-10-06 | 2003-11-16 | Mars Uk Ltd | Estereotipia en animales. |
| KR100701448B1 (ko) | 1999-02-23 | 2007-03-30 | 머크 앤드 캄파니 인코포레이티드 | 양자 펌프 억제제를 함유하는 약제학적 조성물 |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
| DE10061135C1 (de) * | 2000-12-07 | 2002-11-07 | Byk Gulden Lomberg Chem Fab | Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff |
| CA2430816C (en) * | 2000-12-07 | 2012-05-15 | Altana Pharma Ag | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
| WO2002045692A1 (en) * | 2000-12-07 | 2002-06-13 | Altana Pharma Ag | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
| US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| MXPA04007169A (es) * | 2002-01-25 | 2004-10-29 | Santarus Inc | Suministro transmucosal de inhibidores de bomba de protones. |
| CO5400144A1 (es) * | 2002-03-11 | 2004-05-31 | Novartis Ag | Compuestos organicos |
| US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
| CA2490142A1 (en) * | 2002-07-03 | 2004-01-15 | Abbott Laboratories | Liquid dosage forms of proton pump inhibitors |
| US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040081671A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040006109A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| TWI367759B (en) * | 2003-02-20 | 2012-07-11 | Santarus Inc | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid |
| ATE454906T1 (de) * | 2003-07-11 | 2010-01-15 | Astrazeneca Ab | Feste zusammensetzung mit einem protonenpumpenhemmer |
| CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| AU2004257864A1 (en) * | 2003-07-18 | 2005-01-27 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| CA2554271A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| JP2006176461A (ja) * | 2004-12-24 | 2006-07-06 | Dai Ichi Seiyaku Co Ltd | 粒状物 |
| EP1698233A1 (en) * | 2005-03-01 | 2006-09-06 | Bayer HealthCare AG | Reduction of digestibility of phosphorus in animal nutrition |
| US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US20090068263A1 (en) * | 2006-04-20 | 2009-03-12 | Themis Laboratories Private Limited | Multiple unit compositions |
| CH698658B1 (de) * | 2006-04-24 | 2009-09-30 | Mepha Ag | Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole. |
| EP2026768B1 (en) * | 2006-06-01 | 2018-02-28 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| EP2046334B1 (en) | 2006-07-25 | 2014-05-21 | Vecta Ltd. | Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi |
| US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| CA2703008A1 (en) * | 2007-11-15 | 2009-05-22 | Novartis Ag | Anthelmintic paste comprising praziquantel, a macrolide lactone, cyclodextrin and a thickener |
| US20090227633A1 (en) * | 2008-03-04 | 2009-09-10 | Bassam Damaj | Methods to inhibit tumor cell growth by using proton pump inhibitors |
| CN103957894A (zh) * | 2011-10-19 | 2014-07-30 | R.P.谢勒技术有限公司 | 两相药物递送系统 |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| AU2016404808A1 (en) * | 2016-04-29 | 2018-12-13 | Alan Thompson | Veterinary composition |
| CN107468652A (zh) * | 2016-06-07 | 2017-12-15 | 北京新领先医药科技发展有限公司 | 一种固体干混悬温敏凝胶剂及其制备方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CA3033065A1 (en) * | 2016-08-11 | 2018-02-15 | Adamis Pharmaceuticals Corporation | Drug compositions |
| US11564910B2 (en) | 2017-12-08 | 2023-01-31 | Adamis Pharmaceuticals Corporation | Drug compositions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL22368A (en) * | 1963-11-19 | 1969-01-29 | Merck & Co Inc | 2,5(or 6)-bis-heteroaryl substituted benzazoles |
| BE792990A (fr) * | 1971-12-23 | 1973-06-19 | Shell Int Research | Procede de lutte contre les endoparasites chez les chevaux |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5215974A (en) * | 1986-11-21 | 1993-06-01 | Aktiebolaget Hassle | Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-acid secretion related diseases |
| US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| DK130287D0 (da) * | 1987-03-13 | 1987-03-13 | Benzon As Alfred | Oralt praeparat |
| YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| EP2479832A1 (en) | 2009-09-18 | 2012-07-25 | Asahi Glass Company, Limited | Non-aqueous electrolyte for secondary battery |
-
1993
- 1993-04-30 SE SE19939301489A patent/SE9301489D0/xx unknown
-
1994
- 1994-04-06 IS IS4146A patent/IS1694B/is unknown
- 1994-04-07 IL IL10924594A patent/IL109245A/xx not_active IP Right Cessation
- 1994-04-22 LT LTIP1920A patent/LT3263B/lt not_active IP Right Cessation
- 1994-04-22 MA MA23476A patent/MA23170A1/fr unknown
- 1994-04-22 HR HR9301489-2A patent/HRP940267A2/hr not_active Application Discontinuation
- 1994-04-26 PT PT94914665T patent/PT696921E/pt unknown
- 1994-04-26 DK DK94914665T patent/DK0696921T3/da active
- 1994-04-26 PL PL94311276A patent/PL176755B1/pl unknown
- 1994-04-26 AU AU66938/94A patent/AU678830B2/en not_active Ceased
- 1994-04-26 AT AT94914665T patent/ATE199060T1/de not_active IP Right Cessation
- 1994-04-26 JP JP52415994A patent/JP3872509B2/ja not_active Expired - Fee Related
- 1994-04-26 WO PCT/SE1994/000368 patent/WO1994025070A1/en active IP Right Grant
- 1994-04-26 CZ CZ952825A patent/CZ285191B6/cs not_active IP Right Cessation
- 1994-04-26 NZ NZ265728A patent/NZ265728A/en not_active IP Right Cessation
- 1994-04-26 HU HU9503085A patent/HUT74868A/hu unknown
- 1994-04-26 CN CN94191967A patent/CN1100570C/zh not_active Expired - Fee Related
- 1994-04-26 ES ES94914665T patent/ES2155473T3/es not_active Expired - Lifetime
- 1994-04-26 SG SG1996005767A patent/SG52540A1/en unknown
- 1994-04-26 SK SK1354-95A patent/SK280465B6/sk unknown
- 1994-04-26 RU RU95122630/13A patent/RU2131267C1/ru active
- 1994-04-26 EP EP94914665A patent/EP0696921B1/en not_active Expired - Lifetime
- 1994-04-26 BR BR9406363A patent/BR9406363A/pt not_active Application Discontinuation
- 1994-04-26 DE DE69426669T patent/DE69426669T2/de not_active Expired - Fee Related
- 1994-04-26 KR KR1019950704741A patent/KR100324451B1/ko not_active IP Right Cessation
- 1994-04-28 EG EG24594A patent/EG20401A/xx active
- 1994-04-28 TN TNTNSN94035A patent/TNSN94035A1/fr unknown
- 1994-04-29 US US08/235,258 patent/US5731002A/en not_active Expired - Lifetime
- 1994-11-17 EE EE9400377A patent/EE03137B1/xx unknown
-
1995
- 1995-04-27 YU YU22794A patent/YU22794A/sh unknown
- 1995-10-23 NO NO19954240A patent/NO312435B1/no unknown
- 1995-10-27 FI FI955124A patent/FI955124A0/fi not_active Application Discontinuation
-
2001
- 2001-05-07 GR GR20010400679T patent/GR3035831T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP940267A2 (en) | Veterinary composition | |
| JP4603631B2 (ja) | プロトンポンプ阻害剤を含有する医薬組成物 | |
| DE3751851T2 (de) | Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung säurelabiler Verbindungen sind | |
| AU770633B2 (en) | Improved chemical process and pharmaceutical formulation | |
| BR112018001859B1 (pt) | Comprimido, e, método para produzir um comprimido | |
| CN108371657B (zh) | 一种埃索美拉唑镁肠溶微丸的制备方法 | |
| CA2408920C (en) | Methods for prevention of ulcers and improving physiological performance | |
| CA2161683C (en) | Veterinary composition containing a proton pump inhibitor | |
| ZA200103340B (en) | Improved chemical process and pharmaceutical formulation. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBC | Application rejected |